Buprenex (buprenorphine) / Reckitt Benckiser - LARVOL DELTA

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients (clinicaltrials.gov) - P2 | N=20 | Completed | Sponsor: Medical College of Wisconsin | Active, not recruiting ➔ Completed

Trial completion • Head and Neck Cancer • Mucositis • Oncology • Pain • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Comparison of Nonmedical Use of Buprenorphine Products for Analgesia Compared to Other Opioid Medications in Adults Evaluated for Substance Use with the Addiction Severity Index-Multimedia Version (ASI-MV®) (PAINWeek 2024) - "Background: Buprenorphine has been approved for analgesia in the US as an intravenous/intramuscular injection (Buprenex®) since 1982, as a transdermal patch (Butrans®) since 2010, and as a buccal film (Belbuca®) since 2015...However, few studies have directly compared real-world abuse rates between buprenorphine products for analgesia and Schedule II opioid medications4, and have included buprenorphine buccal film in those comparisons which is the most recent buprenorphine product approved for analgesia.Purpose/Objectives: The purpose of this study was to compare the rates of nonmedical use (NMU; misuse/abuse) among four product groups: (1) buprenorphine buccal film, (2) buprenorphine transdermal patch, (3) Schedule II immediate-release opioid formulations (CII-IR; solid oral dosage forms of IR formulations containing hydrocodone, oxycodone, hydromorphone, oxymorphone, and tapentadol), and (4) Schedule II extended-release opioid formulations (CII-ER; solid..."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Pain • Psychiatry • Substance Abuse

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients (clinicaltrials.gov) - P2 | N=20 | Active, not recruiting | Sponsor: Medical College of Wisconsin | Recruiting ➔ Active, not recruiting

Enrollment closed • Head and Neck Cancer • Mucositis • Oncology • Pain • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Idea Exchange: Buprenorphine Formulations: New, Old, and Everything In Between (Presented by Substance Use Disorders Strategies (SUDS) Community) (AAPP 2024) - "The Buprenex injectable buprenorphine was approved in 1985 but it wasn't really until after the approval of Suboxone and Subutex in 2002 that buprenorphine really to become a gold standard treatment option for opioid use disorder. There are a multitude of different buprenorphine formulations that exist, creating a necessary pharmacist role in appropriate use of buprenorphine. This idea exchange will explore various buprenorphine products, highlight similarities and differences, and discuss methods to switch between buprenorphine products."

Substance Abuse

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Medical College of Wisconsin | Trial completion date: Mar 2025 ➔ Sep 2025

Trial completion date • Head and Neck Cancer • Mucositis • Oncology • Pain • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Medical College of Wisconsin | Trial completion date: Aug 2024 ➔ Mar 2025 | Trial primary completion date: Aug 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Head and Neck Cancer • Mucositis • Oncology • Pain • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) - P2 | N=69 | Terminated | Sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | Trial completion date: Dec 2021 ➔ Jan 2023 | Recruiting ➔ Terminated; Futility analysis

Trial completion date • Trial termination • Addiction (Opioid and Alcohol) • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) - P3 | N=9 | Completed | Sponsor: Yale University | Active, not recruiting ➔ Completed | Phase classification: P1/2 ➔ P3 | N=20 ➔ 9

Enrollment change • Phase classification • Trial completion • Addiction (Opioid and Alcohol)

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Medical College of Wisconsin | Trial completion date: Dec 2023 ➔ Aug 2024 | Trial primary completion date: Dec 2022 ➔ Aug 2023

Trial completion date • Trial primary completion date • Head and Neck Cancer • Mucositis • Oncology • Pain • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Opioids for pain. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Addiction (Opioid and Alcohol) • Pain

Buprenorphine and its formulations: a comprehensive review. (PubMed, Health Psychol Res) - "For the purpose of analgesia, three formulations of buprenorphine were developed: IV/IM injectable formulation (Buprenex®), transdermal patch formulation (Butrans®), and buccal film formulation (Belbuca®). Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade®), subdermal implant (Probuphine®), and sublingual tablets (Subutex®). Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations."

Journal • Review • Addiction (Opioid and Alcohol) • Pain • Substance Abuse

Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) - P1/2 | N=20 | Active, not recruiting | Sponsor: Yale University | Trial completion date: Sep 2022 ➔ Dec 2022

Trial completion date • Addiction (Opioid and Alcohol)

Serum Buprenorphine Concentrations and Behavioral Activity in Mice After a Single Subcutaneous Injection of Simbadol, Buprenorphine SR-LAB, or Standard Buprenorphine. (PubMed, J Am Assoc Lab Anim Sci) - "Simbadol is a concentrated formulation of buprenorphine hydrochloride labeled for use in cats with recommended dosing frequency of every 24 h. We measured serum concentrations over time after a single injection of this product in C57BL/6NCrl mice and compared it to standard buprenorphine (Buprenex) and Buprenorphine SR-LAB...We conclude that Simbadol does not offer dosing advantages over the standard buprenorphine formulation when given at 1 mg/kg. Buprenorphine SR-LAB maintained a steady concentration of buprenorphine above 1ng/mL for at least 24 h, and as such is a superior choice for providing long-term analgesia."

Journal • Preclinical • Pain

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients (clinicaltrials.gov) - P2; N=20; Recruiting; Sponsor: Medical College of Wisconsin; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Head and Neck Cancer • Mucositis • Oncology • Pain • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) - P1/2; N=20; Active, not recruiting; Sponsor: Yale University; Trial completion date: Sep 2021 ➔ Sep 2022; Trial primary completion date: Feb 2021 ➔ Feb 2022

Trial completion date • Trial primary completion date • Addiction (Opioid and Alcohol)

Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) - P2; N=90; Recruiting; Sponsor: Pharmacotherapies for Alcohol and Substance Abuse Consortium; Active, not recruiting ➔ Recruiting; Trial completion date: Sep 2021 ➔ Dec 2021; Trial primary completion date: Jun 2021 ➔ Sep 2021

Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients (clinicaltrials.gov) - P2; N=20; Not yet recruiting; Sponsor: Medical College of Wisconsin

Clinical • New P2 trial • Head and Neck Cancer • Mucositis • Oncology • Pain • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

ESRA & ASRA International eCongress (American Society of Regional Anesthesia and Pain Medicine) - "1:00-2:00 pm, Buprenorphine in the Perioperative Period."

Live event

Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine (clinicaltrials.gov) - P3; N=100; Recruiting; Sponsor: Jordan F. Karp; Not yet recruiting -> Recruiting

Enrollment open • Biosimilar

IRLGREY-B: Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine (clinicaltrials.gov) - P3; N=100; Active, not recruiting; Sponsor: Jordan F. Karp; Recruiting ➔ Active, not recruiting; Trial primary completion date: Jan 2017 ➔ Apr 2017

Enrollment closed • Trial primary completion date • Biosimilar • CNS Disorders • Depression

"Buprenex (buprenorphine) dosing, indications, interactions, adverse effects, and more https://t.co/auC4iCkbV9 via @medscape"

Adverse events • Biosimilar

Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) - P2; N=90; Active, not recruiting; Sponsor: Pharmacotherapies for Alcohol and Substance Abuse Consortium; N=135 ➔ 90

Enrollment change • Alzheimer's Disease • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • Tauopathies And Synucleinopathies

Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) - P2; N=135; Active, not recruiting; Sponsor: Pharmacotherapies for Alcohol and Substance Abuse Consortium; Recruiting ➔ Active, not recruiting

Enrollment closed

Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) - P2; N=135; Recruiting; Sponsor: Pharmacotherapies for Alcohol and Substance Abuse Consortium; Not yet recruiting ➔ Recruiting

Enrollment open

Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) - P1/2; N=20; Active, not recruiting; Sponsor: Yale University; Recruiting ➔ Active, not recruiting; Trial completion date: Sep 2019 ➔ Sep 2021; Trial primary completion date: Sep 2019 ➔ Feb 2021

Enrollment closed • Trial completion date • Trial primary completion date